老虎證券

BRIEF-EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment

Reuters
06/20
BRIEF-EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment

June 20 (Reuters) - EMA's CHMP:

  • POSITIVE OPINION WAS ADOPTED FOR OGSIVEO, FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMOURS

  • NINTEDANIB VIATRIS GOT POSITIVE OPINION FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS, CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES

  • RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR REZDIFFRA, FOR TREATMENT OF ADULTS WITH NONCIRRHOTIC MASH

  • RECOMMENDED GRANTING MARKETING AUTHORISATION FOR AUSTEDO FOR TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE TARDIVE DYSKINESIA

  • POSITIVE OPINION FOR TENOFOVIR ALAFENAMIDE FOR TREATMENT OF ADULTS AND ADOLESCENTS INFECTED WITH HIV-1

  • STARTED RE-EXAMINATION OF ITS MARCH 2025 RECOMMENDATION NOT TO GRANT A MARKETING AUTHORISATION FOR KISUNLA ON JUNE 2

Source text: [ID:]

Further company coverage: SWTX.O

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10